Yup. Twice a day, results show up somewhere before 90 days, ceasing treatment after point appears to continue to provide results.
"In phase 1 and 2 studies, UNR844 exhibited a good safety profile and there were no treatment-related study discontinuations. In addition, all patients showed substantial near visual acuity improvements by day 15.3,4 By day 91, 82% of patients had 20/40 or better near vision and 36% had 20/25 or better near vision. Novartis expects the drop to be labeled for use twice daily for approximately 90 days. The effects of this dosing regimen have been found to last up to 7 months without further dosing. "
Article mentions a marketing file year of 2021 but I have read that they did a Phase IIa trial that should finish in 2022 (2023? Can't find the citation ATM)
